Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.

The American journal of gastroenterology - 1 Aug 2014

Roblin Xavier, Rinaudo M, Del Tedesco E, Phelip J M, Genin C, Peyrin-Biroulet L, Paul S

Abstract excerpt

OBJECTIVES: Several decision algorithms based on the measurement of infliximab (IFX) trough levels and antibodies to IFX have been proposed. Whether such algorithms can be extrapolated to the pharmacokinetics of adalimumab (ADA) has yet to be determined. METHODS: A prospective study included all consecutive patients with inflammatory bowel disease (IBD) having a disease flare while being on ADA 40 mg every 2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Algorithms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anti-Inflammatory Agents

Share to Antibodies, Monoclonal, Humanized

Share to Enzyme-Linked Immunosorbent Assay

Share to Inflammatory Bowel Diseases

Share to Predictive Value of Tests

Share to Treatment Outcome

Source

Identifiers

PMID: 24913041
DOI: 10.1038/ajg.2014.146

Genes

ADA
TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.PMID 24913041Read ↗

One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective studySemantic proximity Read ↗

A Prospective Pharmacogenomic Study of Crohn's Disease Patients during Routine Therapy with Anti-TNF-α Drug Adalimumab: Contribution of ATG5, NFKB1, and CRP Genes to Pharmacodynamic Variability.Semantic proximity Read ↗

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients: From Bedside to Bioinformatics.Semantic proximity Read ↗

Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing.Semantic proximity Read ↗

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.Semantic proximity Read ↗

Fc-gamma receptors type3A (rs396991) genotyping for predicting infliximab efficacy and immunogenicity in ulcerative colitis: An observational study of Iraqi cohort.Semantic proximity Read ↗

Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients.Semantic proximity Read ↗

Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.Semantic proximity Read ↗

Recent advances: Personalised use of current Crohn's disease therapeutic options.Semantic proximity Read ↗

Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.Semantic proximity Read ↗

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.Semantic proximity Read ↗

Identification of HLA-DRB1 association to adalimumab immunogenicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.